Pendopharm announced that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"). Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment TransConTM PTH (palopegteriparatide) in Canada. Financial terms of the agreement are not disclosed.

TransConTM PTH is a parathyroid hormone (PTH) replacement therapy designed to treat chronic hypoparathyroidism, a rare condition caused by absent or insufficient levels of PTH. It is approved under the brand name YORVIPATH® in the European Union, European Economic Area, and Great Britain as a PTH replacement therapy for the treatment of adults with chronic hypoparathyroidism1. TransConTM PTH is also in development for the treatment of adults with chronic hypoparathyroidism in the United States, Japan, and other countries.

A leading Canadian Parathyroidologist Dr. Aliya Khan noted that TransConTM PTH will be the first approved treatment option available to Canadian patients living with chronic hypoparathyroidism. This new partnership aligns with Pharmascience's ambition to establish itself as a leading organization in the life sciences ecosystem.